Halozyme Therapeutics, Inc.

Robbins LLP Is Investigating the Officers and Directors of Halozyme Therapeutics, Inc. on Behalf of Shareholders

Robbins LLP is investigating whether certain officers and directors of Halozyme Therapeutics, Inc. (NASDAQ: HALO) breached their fiduciary duties to shareholders. Halozyme is a biopharmaceutical company that researches, develops, and commercializes human enzymes that facilitate the delivery of injected drugs and fluids.

View the investigation on the law firm’s Shareholder Rights Blog: www.robbinsarroyo.com/shareholders-rights-blog/halozyme-therapeutics-inc/

Halozyme Shares Drop on Halt of PEGPH20 Phase 2 Trial

On April 4, 2014, Halozyme issued a press release announcing that patient enrollment and dosing of PEGPH20 would be halted in the Phase 2 trial of evaluating PEGPH20 in patients with pancreatic cancer. The suspension of the trial followed the recommendation of the independent Data Monitoring Committee, while it assess “clinical data that indicates a possible difference in the thromboembolic event rate between the group of patients treated with PEGPH20, nab-paclitaxel and gemcitabine versus the group of patients treated with nab-paclitaxel and gemcitabine without PEGPH20.” On this news, shares of Halozyme fell $3.16, or 27%, to close at $8.43 on April 4, 2014. Then on April 9, 2014, Halozyme announced that the U.S. Food and Drug Administration had placed a clinical hold on patient enrollment and dosing of PEGPH20.

Halozyme Residential Shareholders Have Legal Options

Robbins LLP highlights that Halozyme shareholders have the option to pursue a shareholder litigation demand or shareholder derivative action through which shareholders aim to hold insider wrongdoers accountable for their actions, prevent future misconduct, and bring long-term value back to the company.

Concerned shareholders who would like more information about their rights and potential remedies can contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.

Send us a message for more information.